

# Evaluation of Cannabis and Cannabinoid Product Use, Knowledge and Attitudes in the Eczema Community

Cleo Whiting, BA,<sup>a</sup> Xuejing Duan, PhD,<sup>b</sup> Adam J. Friedman, MD<sup>c</sup>

<sup>a</sup>The George Washington School of Medicine and Health Sciences

<sup>b</sup>Department of Biostatistics, George Washington Milken Institute School of Public Health

<sup>c</sup>Department of Dermatology, The George Washington School of Medicine and Health Sciences

## Introduction

- Eczema is a major inflammatory skin condition worldwide, and the U.S. prevalence has been estimated to be approximately 10% <sup>1,2</sup>
- Research supports targeting the cutaneous endocannabinoid system to treat eczematous dermatoses <sup>3-5</sup>
- There is limited understanding of patient knowledge and utilization of cannabis/cannabis-derived products as treatments for eczema

## Methods

- Survey Monkey™, an online-survey tool, was used to develop the survey and collect responses
- The survey was advertised by the National Eczema Association (NEA) via social media and NEA network dissemination for 6 weeks
- The survey assessed the eczema community on the use, knowledge, and attitudes of a broad scope of cannabis product types

## Acknowledgements

- We would like to thank the GW SMHS Health Services Scholarship Program for supporting this project and the NEA for their collaboration.

## References

Hanifin JM, Reed ML, Drake LA, et al. A population-based survey of eczema prevalence in the United States. *Dermatitis*. 2007;18(2):82-91. doi:10.2310/6620.2007.06034

Silverberg JJ, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. *J Allergy Clin Immunol*. 2013;132(5):1132-1138. doi:10.1016/j.jaci.2013.08.031

Magfour J, Rundle CW, Rietcheck HR, et al. Assessing the effects of topical cannabidiol in patients with atopic dermatitis. *Dermatol Online J*. 2021;27(2):13030/qt8h50k2vs. Published 2021 Feb 15.

Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. *Biochem Pharmacol*. 2018;157:122-133. doi:10.1016/j.bcp.2018.08.022

Trusler AR, Clark AK, Sivamani RK, Shi VY. The Endocannabinoid System and Its Role in Eczematous Dermatoses. *Dermatitis*. 2017;28(1):22-32. doi:10.1097/DER.0000000000000257

## Results

Figure 1. Respondents' Approval of Using Medical Cannabis to Treat Eczema (n=51)




Figure 2. Respondents' Attitudes on Medical Cannabis





Figure 3. Respondents' General Knowledge of Cannabis Products and Cannabinoids



## Results contd.

- 76 survey respondents total
- 69 (90.79%) were individuals diagnosed with eczema; 7 (9.21%) were primary caregivers of a dependent diagnosed with eczema
- Most frequent source: OTC product without dermatologist recommendation (22 [36.07%], n=61)
- Least frequent source: medical cannabis with dermatologist recommendation (2 [3.12%], n=64)
- 100% (n=50) supported medical cannabis use
- ~63% (32, n=51) approved of using medical cannabis to treat eczema
- 94% (47, n=50) would be comfortable seeing a dermatologist who recommended medical cannabis
- 94% (47, n=50) would be interested in learning about using medical cannabis for the treatment of eczema
- ~93% (54, n=58) had never discussed using medical cannabis as treatment with their healthcare provider
- 46.67% (28, n=60) were unsure if OTC cannabis-derived products were regulated by the FDA.

## Conclusions

- Eczema patients are open to learning about cannabinoid therapies and considering their use with dermatologist guidance
- Some are already using OTC products, but few are using medical cannabis
- There exists gaps in knowledge of cannabinoid properties and product regulation by the FDA
- Dermatologists should prepare to counsel patients on cannabinoid applications in dermatology

## Limitations

- Selection bias
- Small sample-size